ESMO 2026 | Sequencing neoadjuvant and adjuvant treatment in melanoma therapy
Georgina Long
• 26 Oct 2026
Georgina Long, PhD, MBBS, FRACP, The University of Sydney, Sydney, Australia, Australia, comments on the evolving treatment landscape for neoadjuvant therapy in melanoma, highlighting the success of current tools and the need to determine optimal sequencing strategies. Translational data suggests patients without high tumor mutation burden or PD-L1 expression who do not achieve good pathologic response may benefit from chemotherapy following neoadjuvant treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
